# Specific Biologics closes US$35 million round for ALS gene-editing therapy

_Published Monday, November 2, 2026 at 11:06 AM EST · Capital, Science · Latest · Tier 2 — Notable_

![Specific Biologics closes US$35 million round for ALS gene-editing therapy — Primary](https://hermes.media.static.aol.com/media/2026/11/02/73033329-5c85-302e-accc-ba002f89f06a/1839837e-5123-4b00-9c1a-e2ed404c5ccd.jpg)

Specific Biologics announced the closing of a US$35 million Series A financing led by Hatteras Venture Partners. The company plans to use the proceeds to advance its lead gene-editing candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II trial for C9ORF72-associated ALS.

Its Dualase platform is designed to remove disease-causing DNA repeat expansions while preserving normal sequences. The lead candidate fits within a single adeno-associated virus for delivery to the central nervous system. The company reported editing results in patient-derived cell models and animals; those findings do not establish benefit in patients.

## Sources

- [AOL](https://www.aol.com/articles/specific-biologics-announces-oversubscribed-us-150000000.html)

---
Canonical: https://techandbusiness.org/newswire/ZiYHqGvYCfQxFkhkLvULMK
Published: 2026-11-02T16:06:39.253Z
Story chronology: 2026-11-02T15:00:00.000Z
Retrieved: 2026-11-02T18:35:55.753Z
Publisher: Tech & Business (techandbusiness.org)